Form 8-K

8-K — Drugs Made In America Acquisition Corp.

Accession: 0001213900-26-035502

Filed: 2026-03-27

Period: 2026-03-23

CIK: 0002028614

SIC: 6770 (BLANK CHECKS)

Item: Entry into a Material Definitive Agreement

Item: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — ea0283803-8k_drugs.htm (Primary)

EX-10.1 — DEFINITIVE INTERIM INVESTMENT AND SPONSOR TRANSITION AGREEMENT (ea028380301ex10-1.htm)

EX-10.2 — INTERIM CONVERTIBLE NOTE (ea028380301ex10-2.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0283803-8k_drugs.htm · Sequence: 1

false

0002028614

2026-03-23

0002028614

DMAA:UnitsEachConsistingOfOneOrdinaryShare0.0001ParValueAndOneRightToReceiveOneeighthOfOneOrdinaryShareMember

2026-03-23

0002028614

DMAA:OrdinarySharesParValue0.0001PerShareMember

2026-03-23

0002028614

DMAA:RightsEachEntitlingHolderToReceiveOneeighthOfOneOrdinaryShareMember

2026-03-23

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or Section 15(d) of the

Securities Exchange Act of 1934

March 23, 2026

Date of Report (Date of earliest event reported)

Drugs Made In America Acquisition Corp.

(Exact Name of Registrant as Specified in Charter)

Cayman Islands

001-42467

99-2394788

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(I.R.S. Employer

Identification Number)

1 East Broward Boulevard, Suite 700

Fort Lauderdale, FL

33301

(Address of Principal Executive Offices)

(Zip Code)

646-726-7074

Registrant’s telephone number, including

area code:

Not Applicable

(Former name or former address, if changed since

last report)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Units, each consisting of one Ordinary share, $0.0001 par value and one right to receive one-eighth of one ordinary share

DMAAU

The Nasdaq Stock Market LLC

Ordinary shares, par value $0.0001 per share

DMAA

The Nasdaq Stock Market LLC

Rights, each entitling the holder to receive one-eighth of one Ordinary Share

DMAAR

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities

Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry into a Material Definitive Agreement.

On March 23, 2026, Drugs Made In America Acquisition

Corp. (the “Company”) issued an interim convertible note (the “Interim Note”) to BV Advisory Partners,

LLC (the “Investor”) in the principal amount of $100,000 (the “Interim Loan”). The Interim Loan

represents an initial loan towards a contemplated $500,000 financing (the “Financing”) pursuant to the Definitive Interim

Investment and Sponsor Transition Agreement dated March 23, 2026 (the “Investment Agreement”) described under Item

8.01 of this Current Report on Form 8-K.

The Interim Note has a maturity date six

months from the date of issuance, unless earlier converted or credited toward the definitive financing under the Investment

Agreement and does not bear interest. Upon the consummation of initial business combination by the Company (a “Business

Combination”), the outstanding principal amount of the Interim Loan may, at the option of the Investor, be converted into

shares of the combined entity at a conversion price equal to a 35% discount to the market price of such shares at the time of

conversion.

The Company intends to use the proceeds of the

Interim Loan for accounting expenses, audit expenses and other expenses related to a Business Combination although it has not yet entered into an agreement for a Business Combination.

Item 2.03 Creation of a Direct Financial Obligation

or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information set forth in Item 1.01 of this

Current Report on Form 8-K regarding the issuance of the Interim Loan is incorporated herein by reference.

The Interim Loan represents a direct financial

obligation of the Company. The Interim Loan is filed as Exhibit 10.3 hereto and is incorporated herein by reference.

Item 8.01 Other Events

On March 23, 2026, the Company entered into the

Investment Agreement with the Investor relating to a proposed financing transaction pursuant to which the Investor indicated its intent

to provide financing to the Company through a convertible note investment, of which the Interim Loan represented the first tranche. Pursuant

to the Investment Agreement, the aggregate amount to be loaned is $500,000. The second tranche of $200,000 will be made within 21 days

with the remainder of the commitment on an as-needed basis. The Company also agreed to use commercially reasonable efforts to provide

the Investor with not less than 40% of the economic benefit equivalent to sponsor-level economics. The Investor has the right but not

the obligation to provide additional funding beyond the $500,000 commitment.

In connection with the Investment Agreement, the Investor has introduced to the Company a potential business combination opportunity involving

an enterprise technology platform focused on artificial intelligence, machine learning, quantum analytics, and cybersecurity solutions,

consistent with the business of Power Analytics Global Corporation.

The Company has commenced preliminary due diligence with respect to

this potential opportunity. As of the date of this report, no letter of intent, term sheet, or definitive agreement has been executed,

and there can be no assurance that any business combination will result from this evaluation.

The foregoing description of the Investment Agreement

and Interim Loan is not complete and is qualified in its entirety by reference to the full text of the Investment Agreement and Interim

Loan, copies of which are filed hereto as Exhibit 10.1 and Exhibit 10.2, respectively.

Item 9.01 Financial Statements and Exhibits.

Exhibit

Number

Description

10.1

Definitive Interim Investment and Sponsor Transition Agreement

10.2

Interim Convertible Note

104

Cover Page Interactive Data File

SIGNATURES

Pursuant to the requirements

of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto

duly authorized.

Dated: March 27, 2026

DRUGS MADE IN AMERICA ACQUISITION CORP.

By:

/s/ Roger Bendelac

Name:

Roger Bendelac

Title:

Chief Executive Officer

EX-10.1 — DEFINITIVE INTERIM INVESTMENT AND SPONSOR TRANSITION AGREEMENT

EX-10.1

Filename: ea028380301ex10-1.htm · Sequence: 2

Exhibit 10.1

DEFINITIVE INTERIM INVESTMENT AND SPONSOR TRANSITION AGREEMENT

Drugs Made in America Acquisition Corp. I (Cayman Islands)

Date: March 23, 2026

1. Parties

This Agreement is entered into between:

BV Advisory Partners, LLC

903 Hudson Street

Hoboken, NJ 07030 (the “Investor”)

and

Drugs Made in America Acquisition Corp. I (the “Company”).

2. Background

The Company confirms that its sponsor entity, Drugs Made in America

Acquisition LLC, is non-operational and subject to legal constraints.

The Investor is introducing a specific target transaction involving

an enterprise AI & ML, Quantum analytics, and cybersecurity platform business consistent with the Power Analytics Global Corporation

opportunity, including integrated AI & ML analytics, cloud, quantum, and cybersecurity technologies.

The Company is pursuing a replacement sponsor and transaction aligned

with this introduced opportunity.

3. Investment Commitment

The Investor shall provide:

- $100,000 immediately;

- $200,000 within twenty-one (21) days;

- up to $500,000 total commitment as required.

Funds shall be used for compliance, Nasdaq, audit, legal and transaction

preparation.

4. Interim Convertible Note

The initial $100,000 shall:

- be deposited into the IOLA account of Thomas J. McCabe, Attorney

at Law;

- be convertible at the sole discretion of the Investor;

- convert at a 35% discount to post-merger market value;

- have a maturity of six (6) months;

- not constitute a claim against the trust account.

5. Sponsor Economics and Transition

The Company shall use good faith and commercially reasonable efforts

to provide the Investor with not less than 40% of the economic benefit equivalent to sponsor-level economics.

Such economics may be achieved through issuance of new securities,

reallocation when legally permissible, or other agreed structures.

The Company shall assist in good faith negotiations for transfer of

sponsor interests when legally permissible.

6. Timeline and Milestones

Within six (6) months:

- advance the specific introduced transaction;

- execute an agreement in principle (LOI / term sheet);

- progress toward a business combination.

The Company shall pursue extension via proxy and engage its investment

bank to renegotiate underwriting fees.

7. Additional Funding and Rights

The Investor shall have the right, but not obligation, to provide additional

financing including extension funding, PIPE, or acquisition financing, with enhanced participation.

8. Exclusivity

Exclusivity is conditioned on funding, and shall be triggered upon

receipt of initial bridge funding amount. If Investor fails to fund, Company may seek third-party financing while preserving

Investor participation rights where practicable.

9. Governance

Investor shall receive information rights and be consulted on material

financing and transaction decisions.

10. Governing Law

This Agreement shall be governed by Cayman Islands law with New York

and/ or New Jersey courts for enforcement.

11. Binding Effect

This Agreement reflects the definitive understanding of the parties,

subject to customary Board ratification.

SIGNATURES

BV ADVISORY PARTNERS, LLC

By:

/s/ Keith Barksdale

Name:

Keith Barksdale

Title:

Managing Member

DRUGS MADE IN AMERICA ACQUISITION CORP. I

By:

/S/ Roger Bendelac

Name:

Roger Bendelac

Title:

CEO

EX-10.2 — INTERIM CONVERTIBLE NOTE

EX-10.2

Filename: ea028380301ex10-2.htm · Sequence: 3

Exhibit 10.2

INTERIM CONVERTIBLE NOTE

Issuer: Drugs Made in America Acquisition Corp. I

Principal Amount: $100,000

Date: March 23, 2026

1. Purpose

This Interim Convertible Note represents bridge financing

provided by the Investor to cover accounting, audit, Nasdaq compliance, legal, and regulatory reporting expenses required for the

Company to remain compliant and to advance the contemplated transaction and extension process.

2. Relationship to Main Financing

This Note serves as the initial funding component of the proposed financing

arrangement between BV Advisory Partners, LLC and/or affiliates, and Drugs Made in America Acquisition Corp. I, and shall be credited

toward the broader commitment of up to $500,000 contemplated by the parties under the Definitive Interim Investment and Sponsor Transition

Agreement dated March 23, 2026.

3. Funding and Deposit

The principal amount of this Note shall be funded by wire transfer

to the IOLA account of Thomas J. McCabe, Attorney at Law, for the benefit of the Company, as follows:

Account Name: Thomas J. McCabe, Attorney at Law IOLA

Bank Name: TD Bank, N.A.

Branch: Long Beach Road

Bank Address: Oceanside, New York

ABA / Routing Number: 026013673 Account Number: 4361730611

Reference / Memo: BV Advisory Partners, LLC – DMAA I Interim

Funding

This Note shall become effective upon credit of funds to such account

or to any successor account designated in writing by the Company or The McCabe Law Firm, P.C. for the Company’s benefit.

4. Use of Proceeds

Proceeds of this Note shall be used exclusively for accounting, audit,

Nasdaq compliance, legal, proxy, extension, and other regulatory and transaction-related expenses of the Company.

5. Conversion

Conversion shall occur solely at the discretion of the lender after

completion of the Company’s business combination transaction.

In the event of such occurrence, the outstanding principal amount may

be converted into shares or equivalent equity interests of the post-merger combined entity at a price reflecting a thirty-five percent

(35%) discount to the market value of such securities at the time of conversion.

6. No Claim Against Trust Account

This Note shall not constitute, and the Investor expressly acknowledges

that it does not create, any claim against the Company’s trust account. Repayment, conversion, or other treatment of this Note shall

be independent of the trust account and subject only to the terms agreed between the parties.

7. Maturity

This Note shall mature six (6) months from the date of issuance, unless

earlier converted, repaid, or credited toward definitive financing documentation between the parties.

8. Governing Law and Jurisdiction

This Note shall be governed by the laws of the Cayman Islands.

For enforcement and dispute resolution, the courts of the State of

New York or the State of New Jersey, USA, shall have jurisdiction. The parties acknowledge that Cayman Islands corporate law principles

shall apply where relevant to corporate matters of the Issuer.

9. Binding Effect

This Note shall be binding upon and inure to the benefit of the parties

hereto and their respective successors and permitted assigns.

Signatures

Investor

BV Advisory Partners, LLC

By:

/s/ Keith Barksdale

Name:

Keith Barksdale

Title:

Managing Member

Date:

March 23, 2026

Drugs Made in America Acquisition Corp.

By:

/s/

Roger E. Bendelac

Name:

Roger E. Bendelac

Title:

Chief Executive Officer

Date:

03/23/2026

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 9

v3.26.1

Cover

Mar. 23, 2026

Document Type

8-K

Amendment Flag

false

Document Period End Date

Mar. 23, 2026

Entity File Number

001-42467

Entity Registrant Name

Drugs Made In America Acquisition Corp.

Entity Central Index Key

0002028614

Entity Tax Identification Number

99-2394788

Entity Incorporation, State or Country Code

Entity Address, Address Line One

1 East Broward Boulevard

Entity Address, Address Line Two

Suite 700

Entity Address, City or Town

Fort Lauderdale

Entity Address, State or Province

Entity Address, Postal Zip Code

33301

City Area Code

646

Local Phone Number

726-7074

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

Units, each consisting of one Ordinary share, $0.0001 par value and one right to receive one-eighth of one ordinary share

Title of 12(b) Security

Units, each consisting of one Ordinary share, $0.0001 par value and one right to receive one-eighth of one ordinary share

Trading Symbol

DMAAU

Security Exchange Name

NASDAQ

Ordinary shares, par value $0.0001 per share

Title of 12(b) Security

Ordinary shares, par value $0.0001 per share

Trading Symbol

DMAA

Security Exchange Name

NASDAQ

Rights, each entitling the holder to receive one-eighth of one Ordinary Share

Title of 12(b) Security

Rights, each entitling the holder to receive one-eighth of one Ordinary Share

Trading Symbol

DMAAR

Security Exchange Name

NASDAQ

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=DMAA_UnitsEachConsistingOfOneOrdinaryShare0.0001ParValueAndOneRightToReceiveOneeighthOfOneOrdinaryShareMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=DMAA_OrdinarySharesParValue0.0001PerShareMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=DMAA_RightsEachEntitlingHolderToReceiveOneeighthOfOneOrdinaryShareMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type: